Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
13-valent Pneumococcal Conjugate Vaccine (TT/DT) Lot-to-lot Consistency in Children 2–5 Years
CTR20232406Phase 4Completed
- Sponsor
- Beijing Minhai Biological
- Start
- Aug 2023
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
A Phase 4 trial of 13-valent pneumococcal polysaccharide conjugate vaccine in Pneumococcal pneumonia (PP), pneumococcal meningitis, acute otitis media (AOM), pneumococcal bacteremia, sponsored by Beijing Minhai Biological. Started Aug 2023; status: completed.
02
Drugs
13-valent pneumococcal polysaccharide conjugate vaccine
03
Conditions
Pneumococcal pneumonia (PP)pneumococcal meningitisacute otitis media (AOM)pneumococcal bacteremia
Beyond the preview
Go deeper on CTR20232406.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20232406.